Is ensidipine good for leukemia patients?

Enasidenib, as a drug targeting a specific type of leukemia, has indeed brought significant effects to leukemia patients.

Ensidipine can specifically inhibit the activity of IDH1 or IDH2 mutant enzymes. This inhibitory effect can block the production of the abnormal metabolite 2-HG, thereby restoring the normal metabolic environment within the cell. This specific inhibition is critical in patients with leukemia who are positive for IDH1 or IDH2 mutations.

In clinical trials, patients who received ensidipine treatment had a significant reduction in the number of leukemia cells and their disease was effectively controlled. For example, in a clinical trial for AML patients with IDH2 mutations, the overall response rate of the patients reached approximately 40%, of which the complete response rate was close to 20%. These data fully demonstrate the potential of ensidipine in the treatment of leukemia.

In addition to directly reducing the number of leukemia cells, ensidipine may further enhance its therapeutic effect by regulating the immune system and improving the bone marrow microenvironment. This means that ensidipine not only targets the leukemia cells themselves, but may also have a positive impact on the patient's overall health.

Ensidipine, as a targeted drug, provides a new treatment option for leukemia patients with positive IDH1 or IDH2 mutations. This targeted treatment strategy is expected to improve patients' quality of life and survival.

However, we also need to be aware of the possible side effects of ensidipine, such as nausea, vomiting, diarrhea, etc. Although most of these side effects are mild to moderate, they still require close attention and prompt treatment.